Skip to content

Coronavirus Pandemic Video Updates, 69-71

Post Overview
    Add a header to begin generating the table of contents

     

    Furthering the discussion on oxidative stress and COVID-19, this week’s MedCram updates dive deeper into the role of NAC (N-Acetylcysteine), von Willebrand Factor, and GSH (glutathione). Check out all the COVID-19 video updates here.

     

    “NAC” Supplementation and COVID-19 (N-Acetylcysteine)

    In our 69th COVID-19 update video, Dr. Seheult continues his conversation on the oxidative stress cycle, focusing on the role of NAC (N-Acetylcysteine). NAC is an antioxidant and disulphide breaking agent, commonly used for Tylenol (acetaminophen) overdose and, as this research suggests, could play a role in recharging GSH (glutathione) in the oxidative stress cycle. Various articles, cited in the notes of this video, offer additional support for NAC in helping prevent and attenuate influenza symptoms. Other studies suggest that NAC helps reduce virus replication, reduce oxidative stress and inflammatory response in pneumonia patients, and improve other cardiovascular and viral conditions. Dr. Seheult ends the video with these questions: could taking NAC orally prevent serious forms of COVID-19, and if given in high enough doses intravenously in the hospital, can NAC prevent patients from progressing to intubation and admission into the ICU?

     

    Glutathione Deficiency, Oxidative Stress, and COVID-19

    In the 70th video update on novel coronavirus, Dr. Seheult looks at statistics on cases, deaths, and testing throughout the United States. He then picks back up on NAC and GSH, addressing questions about simply giving COVID-19 patients GSH instead of its precursor, NAC. Furthermore, case reports from New York and Russia appear to support the hypothesis that GSH deficiency is related to COVID-19 severity. Further clinical trials on GSH and NAC, like this one underway for the treatment of severe COVID-19 infections, are needed to assess these hypotheses. 

     

    New Data on Adding Zinc to Hydroxychloroquine + Azithromycin

    In our 71st COVID-19 video update, Dr. Seheult discusses this retrospective study from NYU Grossman School of Medicine, which looks at the effectiveness of adding zinc to a hydroxychloroquine and azithromycin treatment protocol. All in all, this pre-print research found an increased frequency of patients being sent home and a reduction in mortality, claiming to provide the first in vivo evidence for the treatment of hydroxychloroquine and azithromycin plus zinc sulphate. Dr. Seheult dives deeper into this specific research, examining potential confounding factors, such as lymphocyte and troponin count, the stage of severity at which this treatment was administered, and other nuances which call for further prospective, randomized, controlled trials. 

     

    Stay Tuned for More COVID-19 Updates 

    Please keep in mind that while not all of our COVID-19 updates are available on YouTube, these videos are always available for free (and ad-free) at MedCram.com. While you’re there, check out our full library of lectures on other subjects ranging from ECG interpretation to lung ultrasound interpretation and more.

    Meanwhile, here’s a list of all the COVID-19 resources we’ve shared so far:

    1 Comment

    1. Robert Skinstad on May 25, 2020 at 11:30 pm

      Just a thought, the hypothesis presented with oxidative streess resulting in high VWF and trombosis, may also explain why diabetes and high blood pressure is risk group. Both will impact the status of the blood vessels as I understand it.
      Maybe it is worth explaining the connection

    Leave a Comment